Source: Virtual Congress 2020 – Pulmonary embolism and beyond



Rating:

Share or cite this content

Citations should be made in the following way:
B. Lazovic (Beograd, Republic of Serbia), S. Sarac (Beograd, Republic of Serbia), R. Milic (Beograd, Republic of Serbia), V. Zugic (Beograd, Republic of Serbia). Prevalence of Pulmonary Embolism Among Systemic Lupus Erythematosus patients. 3449

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary Vascular Resistances are Predictors of 3-year-survival in Systemic Sclerosis Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 Association between antiphospholipid antibody type and level and pulmonary manifestations in APS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Exercise Pulmonary Vascular Resistances are Predictors of Survival in Systemic Sclerosis Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 Comparison of Septic and Non-Septic Pulmonary Embolism in Children Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021 Clinical and Epidemiological Features of Tumor and Non-tumor Patients Complicated with Pulmonary Embolism Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Aerobic Training Improves Pulmonary and Systemic Inflammatory and Fibrotic Response in Asthmatics Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 Diagnosis and Treatment of Chronic Pulmonary Embolism Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Diagnosis and Treatment of Chronic Pulmonary Embolism Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 Clinical efficacy of Macitentan in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Plasma derived-exosome microRNAs in Idiopathic Pulmonary Fibrosis of Anti-synthetase syndrome Disease patients Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Pulmonary Embolism Source: Breathe, 15 (4) 360; 10.1183/20734735.ELF154 Year: 2019 Clinical and Epidemiological Features of Lung Cancer Complicated with Pulmonary Embolism Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Clinical Features of Pulmonary Hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021